AML (Acute Myelogenous Leukemia) Clinical Trials

13 recruiting

Frequently Asked Questions

Common questions about AML (Acute Myelogenous Leukemia) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 1

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

AMLMDSLeukemia+2 more
Cullgen (Shanghai),Inc45 enrolled3 locationsNCT07347171
Recruiting
Not Applicable

Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation

AML (Acute Myelogenous Leukemia)ALL (Acute B-Lymphoblastic Leukemia)MDS (Myelodysplastic Syndrome)
Institute of Hematology & Blood Diseases Hospital, China36 enrolled1 locationNCT07297576
Recruiting

Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.

AML (Acute Myelogenous Leukemia)
Fondazione IRCCS Policlinico San Matteo di Pavia14 enrolled1 locationNCT07254312
Recruiting
Phase 3

The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

AML (Acute Myelogenous Leukemia)Down Syndrome (DS)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology100 enrolled1 locationNCT07232134
Recruiting
Early Phase 1

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

AMLAML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China10 enrolled1 locationNCT07126782
Recruiting
Phase 1

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

Hematologic MalignancyAML (Acute Myelogenous Leukemia)Refractory Acute Myeloid Leukemia+3 more
Hangzhou Weben Pharma Co., Ltd18 enrolled1 locationNCT07014449
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)B-ALLMyeloma, Multiple+3 more
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting

Gut Health in Children With Cancer

HLHAML (Acute Myelogenous Leukemia)Burkitt Lymphoma/Leukemia
Great Ormond Street Hospital for Children NHS Foundation Trust40 enrolled1 locationNCT06899581
Recruiting

Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade

AML (Acute Myelogenous Leukemia)
IRCCS Azienda Ospedaliero-Universitaria di Bologna20 enrolled1 locationNCT06874257
Recruiting
Phase 1

CD123-CD16-NK Cells Immunotherapy for AML

AML (Acute Myelogenous Leukemia)NK CellCD123+ Acute Myeloid Leukemia
Chunji Gao9 enrolled1 locationNCT06835140
Recruiting
Phase 2

Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

AML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06783790
Recruiting
Phase 2

Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML

AML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China1,200 enrolled1 locationNCT06635681